Core Insights - The report highlights a strong recovery in the core business of King’s Ray Bio, with a significant increase in revenue and adjusted net profit for 1H25, leading to an upward revision of guidance for the life sciences segment [1][2] - The closing price of King’s Ray Bio is HKD 18.17, with a target price set at HKD 28.75, indicating a potential upside of 58.2% [1] Financial Performance - For 1H25, the company reported a revenue increase of 82% year-on-year to USD 519 million, and an adjusted net profit growth of 510% to USD 178 million [1] - The life sciences segment saw an 11% revenue growth with an adjusted gross margin of 51.0%, and the full-year revenue growth guidance for this segment has been raised to 13-15% [1] - The custom services revenue in the booming bio segment returned to double-digit growth, with 20 new antibody protein drug projects and 30 CGT projects acquired in 1H25 [1] Business Segments - The report details the performance of various business segments: - **Life Sciences**: Revenue growth of 11%, with a full-year growth guidance of 13-15% and a stable gross margin expected [1] - **Booming Bio**: Custom services revenue growth guidance maintained at 15-20%, with expectations for the first non-COVID BLA project in 2H25 [1] - **Baisjie**: Revenue growth of 8% with an adjusted gross margin of 40.4%, focusing on team building and early strain screening [1] Valuation and Ratings - The report maintains a "Buy" rating for King’s Ray Bio, with a slight upward adjustment of revenue forecasts for 2025-2027 by 1-5%, while lowering the net profit forecast for 2025 due to significant net losses [2] - The SOTP (Sum of the Parts) valuation model has been rolled over to 2026, with target valuation multiples for each business segment remaining unchanged [2]

Company Overview - Shanghai Yingduobao Biotechnology Co., Ltd. has been recently established with a registered capital of 500,000 RMB [1] - The legal representative of the company is Chen Fengbo [1] Business Scope - The company operates in various sectors including technology services, development, consulting, and transfer [1] - It is involved in the processing of soil and fertilizers, sales of fertilizers, and research and development of biological organic fertilizers and compound microbial fertilizers [1] - Additional services include agricultural horticulture, pest control for crops, and forestry pest control [1] - The company also engages in smart agricultural management, agricultural scientific research, and testing development [1] - It provides ordinary goods warehousing services, chemical product sales, and specialized chemical product sales [1] - The company is authorized to produce fertilizers, subject to approval from relevant authorities [1]

证券代码：688575 证券简称：亚辉龙 公告编号：2025-045 深圳市亚辉龙生物科技股份有限公司 控股股东、实际控制人兼董事长及部分高管兼核心 技术人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 股东持股的基本情况 截至本公告披露日，深圳市亚辉龙生物科技股份有限公司（以下简称"亚辉 龙"或"公司"）控股股东、实际控制人兼董事长胡鹍辉先生持有公司股份 发行股票前持有的股份及因权益分派转增的股份，均已上市流通；公司副总经理 兼核心技术人员肖育劲先生持有公司股份 2,480,000 股，占公司股份总数的比例 为 0.4348%，上述股份为公司首次公开发行股票前持有的股份、因权益分派转增 的股份及第二类限制性股票激励归属获得的股份，均已上市流通。 ? 减持计划的主要内容 因个人资金需求，胡鹍辉先生计划通过集中竞价、大宗交易方式减持其持有 的公司股份，合计数量不超过 17,112,804 股，占公司股份比例不超过 3%。减持 期间为自本公告披露之日起 15 个交易日后的 3 ...

Group 1 - The "Youth Startup Internship Program 2025" organized by Cyberport and the Hong Kong SAR Government's Home Affairs and Youth Affairs Bureau has successfully concluded, providing 100 internship positions and attracting over 4,300 applications [1] - Cyberport's CEO, Mr. Zheng Songyan, emphasized the organization's commitment to nurturing the next generation of technology talent to help Hong Kong achieve its vision of becoming an international innovation and technology hub [1] - Since its launch in 2021, the program has received over 20,300 applications and provided 400 internship positions, becoming a significant initiative for cultivating technology talent in Hong Kong [1] Group 2 - This year's program received applications from 168 Cyberport companies, with more than half participating for the first time [1] - The selected 100 internship positions cover a wide range of fields, including data analysis, fintech, biotechnology, AI applications, business development, marketing, and design [1] - During the internship period, 18 interns will visit leading companies in the Greater Bay Area, such as Baidu, Meituan, and EHang, to gain insights into the thriving development of tech enterprises in the region and interact with young entrepreneurs [1]

IPO Pipeline Overview - As of August 17, 2025, there are 296 companies in the IPO pipeline, with 28 on the Shanghai Main Board, 37 on the Sci-Tech Innovation Board, 25 on the Shenzhen Main Board, 29 on the Growth Enterprise Market, and 177 on the Beijing Stock Exchange [1] IPO Application Status - The total number of applications processed includes 6 accepted, 237 in inquiry, 14 approved, 23 suspended, and 16 registered [2] Newly Listed Companies - During the period from August 11 to August 17, 2025, two companies were newly listed: Guangdong Academy of Building Research Group Co., Ltd. closed at 34.01 CNY per share with a 418.45% increase and a trading volume of 19.048 billion CNY, while Zhigao Machinery Co., Ltd. closed at 57.66 CNY per share with a 231.19% increase and a trading volume of 1.083 billion CNY [3] New Counseling Records - Four companies received new counseling records: Zhejiang Ouno Machinery Technology Co., Ltd., Jiangsu Handian Biotechnology Co., Ltd., China Aerospace Technology Co., Ltd., and InnoCon Medical Technology (Suzhou) Co., Ltd. [4][5] Approval for Listing - Three companies successfully passed the review process: Zhejiang Kema Friction Materials Co., Ltd., Xi'an Yisiwei Material Technology Co., Ltd., and Harbin Itama Dapeng Industrial Co., Ltd. [6][7][8] Registration Approval - Three companies received registration approval: Zhejiang Jinhua New Materials Co., Ltd., Daoshengtianhe Material Technology (Shanghai) Co., Ltd., and Marco Polo Holdings Co., Ltd. [9] Termination of Review - Only Wuxi Sunshine Precision Machinery Co., Ltd. withdrew its IPO application during this period [10]

Core Viewpoint - UBS has added Kangfang Biotech (09926) to its list of major recommended stocks in the Asia-Pacific region, citing that the overseas potential of its main asset, Edafo, is not fully reflected in the stock price [1] Group 1: Company Analysis - UBS believes that reports of potential collaborations with multinational companies and the upcoming HARMONi study presentation at the 2025 World Lung Cancer Congress will serve as positive catalysts for the stock price [1] - The target price for Kangfang Biotech has been raised from HKD 197.5 to HKD 224.3, with a "Buy" rating assigned [1] - The valuation of Kangfang Biotech is approximately at the median of the biotech stocks covered by UBS, indicating potential for further outperformance [1] Group 2: Sales Forecasts - UBS has increased its peak sales estimate for Edafo from USD 14.6 billion to USD 16.3 billion [1] - The peak sales estimate for another key asset, Kantani, has been raised from USD 2.2 billion to USD 3.4 billion [1]

Market Overview - The Hang Seng Index closed at 25,270.07 points, down 0.98% for the day and up 25.97% year-to-date[5] - The Technology Index decreased by 0.59%, with a year-to-date increase of 24.06%[5] - The Financial Index fell by 1.25%, with a year-to-date increase of 10.29%[5] Corporate Earnings - Kingdee International's interim loss narrowed by 55.14% to approximately 97.74 million RMB, driven by a 22.1% year-on-year revenue growth in cloud subscription services[15] - Kingsray Biotech reported a loss of 25.46 million USD for the interim period, compared to a loss of 175 million USD in the same period last year[7] Investment Insights - Tencent Holdings (700.HK) has a target price of 550 HKD, with a suggested buy price of 480 HKD, currently trading at 554 HKD[11] - Kingdee International (268.HK) is recommended for purchase at 15.4 HKD, with a target price of 17 HKD, currently at 15.96 HKD[15] Economic Indicators - The Hong Kong Monetary Authority reported that 75% of banks are adopting AI, with 90% of positions requiring relevant skills[2] - The U.S. 10-year Treasury yield is at 4.3082%, reflecting a year-to-date decrease of 26.08 basis points[24] Market Trends - The report indicates a potential for further adjustments in the Hong Kong stock market due to ongoing deflationary pressures in mainland China and signs of inflation rebound in the U.S.[9] - The average trading volume in the Hong Kong market decreased by 15.8% to 312.687 billion HKD[7]

Core Viewpoint - UBS has added Kangfang Biopharma to its list of major recommended stocks in the Asia-Pacific region, believing that the overseas potential of its key asset, Edafo, is not fully reflected in its stock price [1] Group 1: Company Potential - UBS highlights that reports of potential collaborations with multinational companies and the upcoming HARMONi study presentation at the 2025 World Lung Cancer Congress serve as positive catalysts for the stock price [1] - The company is also advancing the global registration and research of another key asset, Okanani [1] Group 2: Financial Estimates - UBS has raised its peak sales forecast for Edafo from $14.6 billion to $16.3 billion and for Okanani from $2.2 billion to $3.4 billion [1] - The target price for Kangfang Biopharma has been increased from HKD 197.5 to HKD 224.3, maintaining a "Buy" rating [1]

Market Performance - The China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 1.5% [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 1.3% [1] - The China Securities Biotechnology Theme Index and the China Securities Innovative Drug Industry Index both saw an increase of 0.7% and 0.5% respectively [1] - The CSI 300 Pharmaceutical and Health Index grew by 0.6% [1] - The Hang Seng Innovative Drug ETF (159316) experienced a net subscription of 18 million units, reaching a record high of 1.26 billion yuan [1] Index Details - The Biotechnology ETF tracks the China Securities Biotechnology Theme Index, which focuses on leading A-share biotechnology companies involved in gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [4] - The rolling price-to-earnings (P/E) ratio for the Biotechnology Theme Index is 55.3 times, with a valuation percentile of 0.7% [5] - The Pharmaceutical ETF tracks the CSI 300 Pharmaceutical and Health Index, covering major companies in the pharmaceutical and health sector, including chemical pharmaceuticals, medical services, and medical devices [6][7] - The rolling P/E ratio for the CSI 300 Pharmaceutical and Health Index is 30.7 times, with a valuation percentile of 45.7% [7] ETF Characteristics - The Hang Seng Innovative Drug ETF is the only ETF tracking the innovative drug index, with a low management fee of 0.15% per year and a custody fee of 0.05% per year [9]

Market Performance - The Hang Seng Index opened 197 points lower and closed 249 points or 1% down at 25,270, with a daily trading volume up over 15% to HK$312.687 billion [1] - The Shanghai Composite Index rose 30 points or 0.8% to 3,696, with a turnover of RMB960.6 billion; the Shenzhen Component Index rose 183 points or 1.6% to 11,634, with a turnover of RMB1.28 trillion; the ChiNext Index rose 64 points or 2.6% to 2,534, with a turnover of RMB652.2 billion [2] - The Dow Jones Industrial Average rose 34 points or 0.1% to 44,946; the S&P 500 Index fell 18 points or 0.3% to 6,449; the Nasdaq Composite Index fell 87 points or 0.4% to 21,622 [2] Central Bank Operations - The People's Bank of China conducted a 7 - day reverse repurchase operation worth RMB238 billion at an unchanged rate of 1.4% on the 15th, with a net injection of RMB116 billion after RMB122 billion of reverse repurchases matured. It also carried out a 6 - month buy - out reverse repurchase operation worth RMB500 billion [2] - The central parity rate of the RMB against the US dollar was lowered by 34 points to 7.1371 [2] Corporate News - Huahong Semiconductor is planning to acquire the controlling stake of Shanghai Huili Microelectronics by issuing shares and paying cash, and is currently in contact with potential transaction parties [4] - Argo Biopharma is considering an IPO in Hong Kong, aiming to raise about US$300 million (equivalent to about HK$2.34 billion) [4] - China Shenhua plans a mid - 2025 profit distribution, with the amount not less than 75% and not more than the attributable net profit to shareholders in the first half of the year [4] - Longfor Group issued a profit warning, expecting a 45% drop in profit and a 70% drop in core profit for the six months ended June compared to last year due to the decline in the real estate industry [5] - China Hongqiao reported a 10.1% year - on - year increase in revenue to RMB81.039 billion and a 35% increase in net profit to RMB12.361 billion for the six months ended June, with no interim dividend [5] - Sands China reported a 23.7% year - on - year drop in net profit to US$413 million for the six months ended June, with an interim dividend of HK$0.25 [5] International News - US President Trump and Russian President Putin met in Alaska but did not reach a consensus on a cease - fire in Ukraine. Trump said they discussed land transfer and security guarantees in Ukraine and were close to an agreement, pending Ukraine's approval [3] - Based on the results of the meeting, Trump said he did not think it was necessary to take action regarding China's purchase of Russian oil for the time being and might reconsider in two to three weeks [3] Banking Data - In the first half of 2025, commercial banks in China achieved a cumulative net profit of RMB1.2 trillion. At the end of the second quarter of 2025, the average return on capital was 8.19% and the average return on assets was 0.63% [4]